Abstracts tagged "Disease Activity"

Abstract Number: 0497 • ACR Convergence 2023
Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis
Filippo Fagni¹, Melek Yalcin Mutlu¹, Ioanna Minopoulou¹, Selahattin Alp Temiz², Manuel Krieter³, Georg Schett⁴, Arnd Kleyer⁵, David Simon¹ and Axel Hueber⁶, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²University Hospital Erlangen and Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Dermatology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany
Background/Purpose: International guidelines advise physical activity as complementary measure to drug treatment for patients with RA. However, this can hardly be extrapolated for PsA, for which…
Abstract Number: 0754 • ACR Convergence 2023
Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis
Agnes Loiojen¹, Elise van Mulligen², Annette van der Helm-van Mil³ and Pascal de Jong², ¹Erasmus Medical Center, department of rheumatology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the treatment and follow-up of rheumatoid arthritis (RA) patients, it has become more desirable to detect changes in disease activity through remote monitoring.…
Abstract Number: 1044 • ACR Convergence 2023
Prevalence and Distribution of Sonographic Elementary Lesions in PsA – Results of 2 Cohorts
Ari Polachek¹, Victoria Furer², Sydney Thib³, Liran Mendel², Ori Elkayam² and Lihi Eder⁴, ¹Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Women’s College Research Institute, Toronto, ON, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) can manifest with different musculoskeletal (MSK) features. Ultrasound (US) optimizes the assessment of the different MSK features in PsA. However, there…
Abstract Number: 1303 • ACR Convergence 2023
Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis
Audrey-Anne Couture¹, Nathalie Carrier², Hugues Allard-Chamard³, Sophie ROUX³, Patrick Liang³ and Gilles Boire³, ¹University of Montréal, Montréal, QC, Canada, ²CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ³Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Composite measures (e.g. SDAI) to assess Rheumatoid Arthritis (RA) disease activity incorporate patient (PGA) and evaluator (EGA) global assessments. EGA and PGA are often…
Abstract Number: 1431 • ACR Convergence 2023
Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results
Peter C. Taylor¹, Kurt de Vlam², Philip J. Mease³, Paul M. Peloso⁴, Dieter Wetzel⁵, Apinya Lertratanakul⁶, Nikolai Brun⁷, Brian Wiens⁸, Jan Brandt-Juergens⁹, Edit Drescher¹⁰, Eva Dokoupilova¹¹, Anna Rowińska-Osuch¹², Nadia Abdel-Kader Martin¹³ and Frank Behrens¹⁴, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University Hospitals Leuven, Leuven, Belgium, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁴ACELYRIN, INC., Naples, FL, ⁵toclinco GmbH, Freiburg im Breisgau, Germany, ⁶ACELYRIN, Chicago, IL, ⁷Affibody AB, Solna, Sweden, ⁸ACELYRIN, Inc., Half Moon Bay, CA, ⁹rheumatologische Schwerpunktpraxis, Berlin, Germany, ¹⁰Csolnoky Ferenc Hospital / Vital Medical Center Private Clinci, Veszprém, Hungary, ¹¹Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ¹²ETG Warszawa, Warsaw, Poland, ¹³Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany
Background/Purpose: Izokibep is a novel small protein IL-17A inhibitor, unique for its high IL-17A binding affinity, a small size at 18.6 kD and albumin binding…
Abstract Number: 1868 • ACR Convergence 2023
Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial
Signe Møller-Bisgaard¹, Kim Hørslev-Petersen², Lykke Ørnbjerg¹, Bo Ejbjerg³, Merete L Hetland¹, Jakob Moeller⁴, Robin Christensen⁵, Sabrina Mai Nielsen⁶, Daniel Glinatsi⁷, Mikael Boesen⁸, Kristian Stengaard-Pedersen⁹, Ole Rintek Madsen¹⁰, Bente Jensen¹¹, Jan Alexander Villadsen², Ellen-Margrethe Hauge⁹, Oliver Hendricks², Hanne Merete Lindegaard¹², Niels Steen Krogh¹³, Anne Grethe Jurik⁹, Henrik Thomsen⁴ and Mikkel Østergaard¹⁴, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ³Slagelse Hospital, Slagelse, Denmark, ⁴Herlev-Gentofte Hospital, Herlev, Denmark, ⁵Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, ⁸Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ⁹Aarhus University Hospital, Aarhus, Denmark, ¹⁰Herlev-Gentofte Hospital, Gentofte, Denmark, ¹¹Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ¹²Odense Hospital, Odense, Denmark, ¹³ZiteLab ApS, Frederiksberg, Denmark, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Radiographic joint damage progresses in 20-30% of rheumatoid arthritis (RA) patients despite fulfilling clinical remission criteria (1). Osteitis assessed on MRI is a well…
Abstract Number: 2236 • ACR Convergence 2023
Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Jeffrey R Curtis¹, Atul Deodhar², Enrique Soriano³, Emmanouil Rampakakis⁴, May Shawi⁵, Natalie shiff⁶, Marcie Strauss⁷, Chenglong Han⁸, William R Tillett⁹ and Dafna Gladman¹⁰, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷MEDASOURCE, Medical Group, Indianapolis, IN, ⁸Immunology, Janssen Global Services, LLC, Malvern, PA, ⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Guselkumab (GUS) has demonstrated robust efficacy across key PsA domains at Week (W) 24, with effects sustained or further enhanced through 2 years. Timing…
Abstract Number: 2343 • ACR Convergence 2023
Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications
Eduardo Mantovani Cardoso¹, Rachel Simon¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by multi-systemic involvement and difficult-to-predict disease flares. Hydroxychloroquine (HCQ) has long been recognized as…
Abstract Number: 0333 • ACR Convergence 2023
Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Heather Lapidus Glassner and Elizabeth Luce, MyHealthTeam, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) leads to symptoms of pain, stiffness, swelling, and fatigue. Patients often report periods of increased symptoms (flares) followed by remission.The purpose…
Abstract Number: 0505 • ACR Convergence 2023
Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study
Shashank Cheemalavagu¹, Yuxuan Jin² and M. Elaine Husni³, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Achieving minimal disease activity (MDA) is an important treatment goal in psoriatic arthritis (PsA), as it leads to improved clinical outcomes and quality of…
Abstract Number: 0778 • ACR Convergence 2023
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Anirudh Subramanian Muralikrishnan¹, Barbara Dreo², Angelika Lackner¹, Rusmir Husic³, Florentine Moazedi-Fuerst³, Josef Hermann⁴, Philipp Bosch¹, Johannes Fessler¹, Jens Thiel⁵ and Martin Stradner¹, ¹Medical University of Graz, Graz, Austria, ²Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Meduni Graz, Graz, Austria, ⁴Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany
Background/Purpose: Psoriatic Arthritis (PsA) is a painful disease of the joints and spine. Recent studies have described enteric dysbiosis as a possible pathological mechanism in…
Abstract Number: 1045 • ACR Convergence 2023
Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis
Tadashi Okano¹, Kenji Mamoto¹, Yutaro Yamada¹, Shohei Anno², Asami Yagami¹, Yuka Domae¹, Shingo Washida¹, Yuko Yoshida¹, Tatsuya Koike³ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: In recent years, the concept of D2T RA (difficult-to-treat rheumatoid arthritis) has become widespread, and D2T RA patients are defined as a state in…
Abstract Number: 1313 • ACR Convergence 2023
Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis
Brian Andonian, Leanna Ross, Alyssa Sudnick, Johanna Johnson, Carl Pieper, Connie Bales, Kathryn Porter Starr, William Kraus and Kim Huffman, Duke University, Durham, NC
Background/Purpose: Older persons with rheumatoid arthritis (RA) are at increased risk for sarcopenic obesity, physical disability, adverse drug events, and cardiovascular disease; thus, there is…
Abstract Number: 1437 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study
William R Tillett¹, Joseph Merola², Yoshiya Tanaka³, Ennio G Favalli⁴, Dennis McGonagle⁵, Jessica A Walsh⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Vanessa Taieb⁹ and Christopher T Ritchlin¹⁰, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁵Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom, ⁶Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Colombes, France, ¹⁰University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Given the chronic nature of PsA, sustaining high levels of disease control with treatment is important. Assessing maintenance of response in patients (pts) that…
Abstract Number: 1896 • ACR Convergence 2023
Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale
Pamela Gonzalez Manrique¹, Vinit Gilvaz², Ravinder Kaler³, Neha Batra³ and Anthony Reginato², ¹Roger Williams Medical Center, North Providence, RI, ²The Warren Alpert Medical School of Brown University, Providence, RI, ³Roger Williams Medical Center, Providence, RI
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by inflammatory polyarthritis with infrequent extra-articular involvement. The management of RA typically requires frequent clinic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.